Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

NCT01556594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoglycemia

Interventions

DRUG: Nasal Glucagon 1 mg
DRUG: Nasal Glucagon 2 mg
DRUG: SC Glucagon
DRUG: Nasal Glucagon 3 mg

Sponsor

Eli Lilly and Company

Collaborators

[object Object]